BioNotebook: Bayer invests in Versant's VC fund; corporate venture data; Triphase/Celgene deals
This article was originally published in Scrip
Executive Summary
Bayer HealthCare will invest up to $25m in the fifth venture capital fund raised by Versant Ventures, which may exceed $300m, to finance early-stage therapeutic innovation and extend the company's relationship with the VC firm.
You may also be interested in...
With Celgene Acquisition Closed, Bristol Faces Major Milestones
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
Billions On The Line With Celgene’s Partnered Pipeline
Celgene’s fourth quarter and 2016 sales aligned with previously disclosed double-digit gains as the company outlined later-stage pipeline programs expected to add billions in sales during the next five years.
Bayer's CoLaborator: A Startup Hub In San Francisco's Biotech Cluster
Bayer is incubating startups and nurturing companies that could be the big pharma's next partners at its CoLaborator in San Francisco's Mission Bay, the heart of the region's biotech hub.